VEGFA and hereditary clear cell renal cell carcinoma: Similarly, bevacizumab, a vascular endothelial growth factor A (VEGFA)-neutralizing mAb approved for the treatment of glioblastoma multiforme, CRC, as well as cervical carcinoma, renal cell carcinoma (RCC) and lung carcinoma, not only exerts anti-angiogenic effects [50, 73], but also boosts tumor infiltration by B and T lymphocytes, [74, 75], while inhibiting CD4+CD25+FOXP3+ regulatory T cells (Tregs) [76].